全文获取类型
收费全文 | 241篇 |
免费 | 5篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 13篇 |
妇产科学 | 2篇 |
基础医学 | 7篇 |
口腔科学 | 6篇 |
临床医学 | 19篇 |
内科学 | 55篇 |
皮肤病学 | 6篇 |
神经病学 | 11篇 |
特种医学 | 16篇 |
外科学 | 17篇 |
综合类 | 7篇 |
预防医学 | 2篇 |
眼科学 | 5篇 |
药学 | 10篇 |
肿瘤学 | 72篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2018年 | 2篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 10篇 |
2014年 | 13篇 |
2013年 | 11篇 |
2012年 | 5篇 |
2011年 | 8篇 |
2010年 | 9篇 |
2009年 | 8篇 |
2008年 | 12篇 |
2007年 | 5篇 |
2006年 | 8篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 16篇 |
2002年 | 13篇 |
2001年 | 15篇 |
2000年 | 10篇 |
1999年 | 12篇 |
1998年 | 7篇 |
1997年 | 6篇 |
1996年 | 11篇 |
1995年 | 3篇 |
1994年 | 4篇 |
1993年 | 3篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1982年 | 5篇 |
1980年 | 1篇 |
1978年 | 2篇 |
1976年 | 1篇 |
排序方式: 共有250条查询结果,搜索用时 15 毫秒
1.
Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin
W Scheithauer H Rosen R Schiessel J Schüller M Karall F Ernst C Sebesta G Kornek E Hentschel A Marczell 《Cancer》1991,67(5):1294-1298
Based on in vitro studies that have demonstrated synergy between 5-fluorouracil (5-FU), leucovorin (LV), and cisplatin (CDDP) against human colon cancer cell lines, a clinical trial was initiated to determine the effects of this combination in patients with advanced unresectable colorectal carcinoma. Fifty-nine patients were enrolled in the study and 12 of them had received prior conventional 5-FU chemotherapy. Treatment consisted of 4 weekly courses of high-dose LV (200 mg/m2) administered by intravenous (IV) bolus, followed by 5-FU (550 mg/m2) and CDDP (20 mg/m2) each administered as a 2-hour infusion on 4 consecutive days. After a median of 5.5 treatment cycles, objective tumor response was seen in 20 of 59 patients (34%) (this included 3 complete remissions). The response rate in the 47 previously untreated patients was 38% (95% confidence limits, 26% to 53%). Stable disease occurred in 16 (27%) patients, whereas the tumor progressed in 23 (39%) patients. The median survival time was 11.5 months, with 15% of the patients alive at 2 years. The regimen was well tolerated and the primary side effects were mild and reversible gastrointestinal symptoms and myelosuppression. There was no episode of life-threatening toxicity. Eastern Cooperative Oncology Group (ECOG) Grade III adverse reactions that required 25% dose reductions occurred in only 14% of the patients. The results of this trial suggest that 5-FU, LV, and CDDP is an active, safe, and well-tolerated combination regimen in patients with advanced colorectal cancer. 相似文献
2.
M. Hejna G. V. Kornek M. Raderer J. Valencak G. Weinländer W. Fiebiger J. Miholic W. Scheithauer 《Annals of oncology》1998,9(12):1309-1314
Background: To determine the maximum tolerable dose (MTD) and therapeutic activity of MTHF-modulated FU using two different administration schedules of the antimetabolite (bolus vs. two-hour infusion), the present randomized study using a 'pick-the-winner' design was undertaken in patients with advanced colorectal cancer.Patients and methods: Eighty-two patients with previously untreated advanced measurable colorectal cancer were randomly assigned to treatment with MTHF (100 mg/m2 days 1–5 i.v. bolus) plus FU (400 mg/m2 days 1–5) given either as i.v. bolus injection or as a two-hour infusion every four weeks. In the absence of dose-limiting toxicity (DLT, defined as WHO grade 3 hematotoxicity and/or WHO grade 2 nonhematologic side effects) and evidence of progressive disease, the FU dose was escalated by 50 mg/m2/day during each subsequent cycle until the individual maximum tolerable dose (MTD) was reached.Results: Forty patients were randomized to the FU bolus arm and 42 patients to the FU two-hour infusion arm. The median MTD was 475 mg/m2/day (95% CI: 450–500) in the FU bolus arm with stomatitis ± diarrhea being the most common DLT. Gastrointestinal side effects were also dose-limiting in the two-hour infusion arm; however, the median MTD was 600 mg/m2/day (95% CI: 568–632). Myelosuppression was more pronounced in the FU bolus arm than in the two-hour infusion arm. The overall response rates were 27.5% (95% CI: 15–44%; 1 CR and 10 PR) for patients treated in the bolus arm and 14.5% (95% CI: 5–28%; 1 CR and 5 PR) for those treated in the two-hour infusion arm. Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.Conclusions: The observed differences in tolerable drug dose and toxicity between the two treatment arms might be explained by the administration schedule-dependent clinical pharmacokinetics of FU and/or the difference in extent of biochemical modulation of the antimetabolite through MTHF. The fact that the two regimens were not equitoxic probably also helps to explain the favourable response activity noted in the MTHF/FU bolus arm. Whether MTHF is as effective as leucovorin for biochemical modulation of FU remains to be determined in a randomized trial, for which we would recommend its combined use with bolus FU ('winner arm') using a starting dose of 400 mg/m2/day ×5. 相似文献
3.
4.
5.
The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells 总被引:15,自引:16,他引:15
Sitnicka E; Lin N; Priestley GV; Fox N; Broudy VC; Wolf NS; Kaushansky K 《Blood》1996,87(12):4998-5005
In this study, we explored whether thrombopoietin (Tpo) has a direct in vitro effect on the proliferation and differentiation of long-term repopulating hematopoietic stem cells (LTR-HSC). We previously reported a cell separation method that uses the fluorescence-activated cell sorter selection of low Hoescht 33342/low Rhodamine 123 (low Ho/low Rh) fluorescence cell fractions that are highly enriched for LTR-HSC and can reconstitute lethally irradiated recipients with fewer than 20 cells. Low Ho/low Rh cells clone with high proliferative potential in vitro in the presence of stem cell factor (SCF) + interleukin-3 (IL-3) + IL-6 (90% to 100% HPP-CFC). Tpo alone did not induce proliferation of these low Ho/low Rh cells. However, in combination with SCF or IL-3, Tpo had several synergistic effects on cell proliferation. When Tpo was added to single growth factors (either SCF or IL-3 or the combination of both), the time required for the first cell division of low Ho/low Rh cells was significantly shortened and their cloning efficiency increased substantially. Moreover, the subsequent clonal expansion at the early time points of culture was significantly augmented by Tpo. Low Ho/low Rh cells, when assayed in agar directly after sorting, did not form megakaryocyte colonies in any growth condition tested. Several days of culture in the presence of multiple cytokines were required to obtain colony-forming units-megakaryocyte (CFU-Mk). In contrast, more differentiated, low Ho/high Rh cells, previously shown to contain short- term repopulating hematopoietic stem cells (STR-HSC), were able to form megakaryocyte colonies in agar when cultured in Tpo alone directly after sorting. These data establish that Tpo acts directly on primitive hematopoietic stem cells selected using the Ho/Rh method, but this effect is dependent on the presence of pluripotent cytokines. These cells subsequently differentiate into CFU-Mk, which are capable of responding to Tpo alone. Together with the results of previous reports of its effects on erythroid progenitors, these results suggest that the effects of Tpo on hematopoiesis are greater than initially anticipated. 相似文献
6.
G. Kornek D. Depisch E. M. Temsch W. Scheithauer 《Journal of cancer research and clinical oncology》1991,117(5):493-496
Summary To establish further the clinical significance of the CA-195 tandem immunoradiometric assay in gastrointestinal malignancies, the sera of a total of 222 subjects have been analysed and compared with assays of the classical gastrointestinal tumour markers, CA19-9 and carcinoembryonic antigen (CEA). CA-195 elevations above normal (>10 U/ml) were noted in 51/72 (70.8%) colorectal, 15/15 (100%) pancreatic, and in 6/12 (50%) gastric cancer patients. Whereas CA19-9 was increased (>37 U/ml) in 65%, 93%, and 42% of cases, only 54% colorectal, 45% pancreatic, and 42% gastric cancer patients had pathologically elevated serum CEA levels (>5 ng/ml). No abnormal increase of both CA-195 and CA19-9 was found in healthy volunteers, whereas 3/20 (smoking) individuals had CEA levels slightly above normal. With a 29% false-positive rate noted among 103 patients with benign gastroinestinal disorders, the specifity of CA-195 was superior to that of CA19-9 (58%) and comparable with that of CEA (31%). A significant correlation between CA-195 levels and the clinical/pathological stage of disease was noted in colorectal (P<0.01) and pancreatic cancer patients (P<0.007). Preliminary results of serial measurements of CA-195 in colorectal cancer suggest that this new marker protein, which has no cross-reactivity with CEA, may be useful as a non-invasive test for postoperative surveillance of patients to detect disease recurrence, and serve to complement (though certainly not replace) standard clinical measurements of response to chemotherapy.Abbreviation CEA
carcinoembryonic antigen 相似文献
7.
GV Ramesh Prasad Marcel Ruzicka Kevin D Burns Sheldon W Tobe Marcel Lebel 《The Canadian journal of cardiology》2009,25(5):309-314
For the first time, the Canadian Hypertension Education Program has studied the evidence supporting blood pressure control in people requiring renal replacement therapy for end-stage kidney disease, including those on dialysis and with renal transplants. According to the Canadian Organ Replacement Registry’s 2008 annual report, there were an estimated 33,832 people with end-stage renal disease in Canada at the end of 2006, an increase of 69.7% since 1997. Of these, 20,465 were on dialysis and 13,367 were living with a functioning kidney transplant. Thus, it is becoming more likely that primary care practitioners will be helping to care for these complex patients. With the lack of large controlled clinical trials, the consensus recommendation based on interpretation of the existing literature is that blood pressure should be lowered to below 140/90 mmHg in hypertensive patients on renal replacement therapy and to below 130/80 mmHg for renal transplant patients with diabetes or chronic kidney disease. 相似文献
8.
AE Scaramuzza A De Palma C Mameli D Spiri L Santoro GV Zuccotti 《Acta paediatrica (Oslo, Norway : 1992)》2010,99(8):1237-1241
Aim: The aim of the student is to assess whether adolescents with type 1 diabetes mellitus (T1DM) in Italy differ from their healthy peers in regard to risky behaviour. Methods: Data were collected from 215 patients, aged 14 ± 2 years with a mean disease duration of 7 ± 5 years. The control group was comprised of 464 healthy adolescents recruited among high school students. Each patient completed an anonymous confidential questionnaire to determine the prevalence of sexual behaviour, alcohol and tobacco consumption, illicit drug use, and, among patients with diabetes and frequency of mismanagement related to diabetes care. Results: Compared with controls, subjects with diabetes showed a similar rate of sexual intercourse among males and lower rates among females (34.8% vs 35.5%, p NS and 29.4% vs 41.4%, p < 0.05, respectively). Males in the diabetes group reported a higher rate of tobacco use, whereas females showed similar or higher rates of use for every illicit drug studied. Among patients with diabetes, those who are engaged in risky behaviour showed a higher rate of treatment mismanagement (76% vs 34%, p < 0.01). Conclusion: Adolescents with T1DM are as likely as their healthy peers to engage in risky behaviour, indicating the potential benefit of anticipatory guidance concerning glycaemic control and increased risk of acute and chronic complications. 相似文献
9.
GV Coppa P Pierani L Zampini I Carloni A Carlucci O Gabrielli 《Acta paediatrica (Oslo, Norway : 1992)》1999,88(S430):89-94
Twenty-one oligosaccharides of human milk were quantified by high-performance anion-exchange chromatography. Milk samples were collected from 18 mothers during the first 3 mo of lactation. The data show that the highest amount of all oligosaccharides is present at day 4 postpartum (20 g l−1 ) and then decreases by about 20% at day 30 of lactation. The protective role played by these substances against different infectious agents, in different organs and systems of the breastfed baby, is emphasized. 相似文献
10.
Bernier J.; Bonner J; Vermorken J. B.; Bensadoun R.-J.; Dummer R.; Giralt J.; Kornek G.; Hartley A.; Mesia R.; Robert C.; Segaert S.; Ang K. K. 《Annals of oncology》2008,19(1):142-149
Background: Radiation dermatitis occurs to some degree in mostpatients receiving radiotherapy, with or without chemotherapy.Patients with squamous cell carcinoma of the head and neck (SCCHN)who receive radiotherapy in combination with epidermal growthfactor receptor (EGFR) inhibitors, such as cetuximab, may developa characteristic acne-like rash in addition to dermatitis. Design: An advisory board of 11 experienced radiation oncologists,medical oncologists and dermatologists discussed the managementoptions for skin reactions in patients receiving EGFR inhibitorsand radiotherapy for SCCHN. Skin toxicity was categorised accordingto the National Cancer Institute—Common Terminology Criteriafor Adverse Events (version 3) grading. Results: Both general and grade-specific approaches for themanagement of dermatitis in this patient group are presented.It was concluded that where EGFR inhibitor-related acne-likerash and dermatitis coexist within irradiated fields, managementshould be based on the grade of dermatitis: for grade 1 (orno dermatitis), treatment recommendations for EGFR-related acne-likerash outside irradiated fields should be followed; for grades2 and above, treatment recommendations for dermatitis were proposed. Conclusions: This paper presents comprehensive consensus guidelinesfor the treatment of dermatitis in patients with SCCHN receivingEGFR inhibitors in combination with radiotherapy. Key words: cetuximab, EGFR inhibitors, radiation dermatitis, radiotherapy, skin reactions, squamous cell carcinoma of the head and neck
Received for publication June 26, 2007. Revision received July 12, 2007. Accepted for publication July 12, 2007. 相似文献